<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04959253</url>
  </required_header>
  <id_info>
    <org_study_id>252750</org_study_id>
    <nct_id>NCT04959253</nct_id>
  </id_info>
  <brief_title>Psilocybin in Depression Resistant to Standard Treatments</brief_title>
  <acronym>PsiDeR</acronym>
  <official_title>A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South London and Maudsley NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single centre clinical trial to evaluate the feasibility, safety and efficacy of&#xD;
      psilocybin, given under supportive conditions, in a randomised, blinded design in adult&#xD;
      participants with treatment resistant major depressive disorder. The primary objective is to&#xD;
      evaluate feasibility by measuring recruitment rates, dropout rates and by estimating the&#xD;
      variance of the primary outcome measure (MADRS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>3 weeks from baseline. Lower score is a better outcome.</time_frame>
    <description>Investigator rated depression scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms SR 16</measure>
    <time_frame>3 weeks from baseline. Lower score is a better outcome.</time_frame>
    <description>Participant rated depression scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <arm_group>
    <arm_group_label>Psilocybin 25mg PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo PO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Psilocybin assisted therapy</intervention_name>
    <description>A package of psychological therapy and a single dosing session of psilocybin.</description>
    <arm_group_label>Psilocybin 25mg PO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo assisted therapy</intervention_name>
    <description>A package of psychological therapy and a single dosing session of placebo.</description>
    <arm_group_label>Placebo PO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 25 - 80 years&#xD;
&#xD;
          -  Fluent in the English language&#xD;
&#xD;
          -  Fulfil Diagnostic and Statistical Manual of Mental Disorders (5th Edition) (DSM-5)&#xD;
             criteria for a primary diagnosis of current single or recurrent episodes of MDD of at&#xD;
             least moderate severity but without psychotic features as defined on the MINI 7.0.&#xD;
             Positive and primary diagnoses on the MINI 7.0 will be subject to confirmation at&#xD;
             clinical interview by a psychiatrist.&#xD;
&#xD;
          -  17-item HAM-D score ≥ 14.&#xD;
&#xD;
          -  Have failed to respond to 2 or more antidepressants prescribed at the minimum&#xD;
             effective dose for at least 6 weeks OR at least 1 antidepressant prescribed at the&#xD;
             minimum effective dose for at least 6 weeks AND a course of evidence-based&#xD;
             psychotherapy given for at least 6 sessions.&#xD;
&#xD;
          -  For those aged ≥ 60 years, the first episode of depression must have started prior to&#xD;
             their 60th birthday.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of bipolar disorder (defined as meeting DSM-5 criteria for bipolar 1 or&#xD;
             bipolar 2) on the MINI 7.0. Positive diagnoses on the MINI will be subject to&#xD;
             confirmation at clinical interview by a psychiatrist.&#xD;
&#xD;
          -  Diagnosis of psychotic disorder (defined as meeting DSM-5 criteria for any psychotic&#xD;
             disorder) on the MINI 7.0, EXCEPT substance/medication induced psychotic disorder&#xD;
             where the duration was limited to the acute period of direct intoxication with the&#xD;
             substance/medication. Positive diagnoses on the MINI will be subject to confirmation&#xD;
             at clinical interview by a psychiatrist.&#xD;
&#xD;
          -  Diagnosis of drug or alcohol dependence syndrome (defined as meeting DSM-5 criteria&#xD;
             for any dependence syndrome) on the MINI 7.0. Positive diagnoses on the MINI will be&#xD;
             subject to confirmation at clinical interview by a psychiatrist.&#xD;
&#xD;
          -  Diagnosis of any personality disorder (defined as meeting DSM-5 criteria for any&#xD;
             personality disorder) based on clinical interview and the MINI 7.0. Positive diagnoses&#xD;
             on the MINI will be subject to confirmation at clinical interview by a psychiatrist.&#xD;
&#xD;
          -  Diagnosis of any dementia (defined as meeting DSM-5 criteria for any dementia&#xD;
             disorder) based on clinical interview by a psychiatrist.&#xD;
&#xD;
          -  Personal history of a ≥ 1 suicide attempt in the past year requiring hospitalization,&#xD;
             defined using the CSSRS (Q6 (past year) = &quot;y&quot;) and clinical interview with a&#xD;
             psychiatrist.&#xD;
&#xD;
          -  Other personal circumstances and behaviour judged to be incompatible with&#xD;
             establishment of rapport or safe exposure to psilocybin.&#xD;
&#xD;
          -  Depression secondary to other medical conditions&#xD;
&#xD;
          -  Medical diagnosis incompatible with psilocybin treatment&#xD;
&#xD;
          -  Inability to provide a screening blood sample, urine sample or electrocardiogram.&#xD;
&#xD;
          -  Biochemical abnormalities (defined as falling outside the normal reference range) as&#xD;
             evaluated by a full blood count, full biochemistry profile and thyroid function tests.&#xD;
             Biochemical abnormalities must also be determined as clinically significant by a&#xD;
             medical doctor to fulfil the criterion for exclusion.&#xD;
&#xD;
          -  Electrocardiographic abnormalities, defined as any abnormality that is not normal&#xD;
             sinus rhythm and determined as clinically significant by a medical doctor.&#xD;
&#xD;
          -  Women of child bearing potential not using adequate contraception.&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  Those unable to give informed consent.&#xD;
&#xD;
          -  Non-registration with a GP or failure to consent to sharing of the GP summary care&#xD;
             record and any psychiatric assessments held.&#xD;
&#xD;
          -  Those enrolled in another drug trial&#xD;
&#xD;
          -  Hypersensitivity to the IMP or to any of the excipients or placebo&#xD;
&#xD;
        Exclusions for Pre-Existing Medical Conditions&#xD;
&#xD;
        Participants will be excluded if they have a current diagnosis of ≥1 of:&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Hypertension (defined as a systolic blood pressure ≥ 160mm/Hg or a diastolic blood&#xD;
             pressure ≥ 100mm/Hg on three separate readings). All readings of systolic blood&#xD;
             pressure ≥ 140mm/Hg or diastolic blood pressure ≥ 90mm/Hg will be reviewed by a&#xD;
             clinician. Hypertension ascertained prior to dosing will be subject to clinical&#xD;
             confirmation via collateral information from the GP or other source.&#xD;
&#xD;
          -  Cardiac failure, defined as class IV of the New York Heart Association classification&#xD;
&#xD;
          -  Renal failure, defined as ≥ stage 4 (GFR ≤ 29mL/min)&#xD;
&#xD;
          -  Liver failure, defined as a clinical diagnosis of liver fibrosis, cirrhosis of the&#xD;
             liver, liver failure or advanced liver disease.&#xD;
&#xD;
          -  Any cardiac arrhythmia, except atrial fibrillation.&#xD;
&#xD;
          -  Any form of epilepsy&#xD;
&#xD;
        Past diagnosis of ≥1 of:&#xD;
&#xD;
          -  Cerebrovascular accident or intracerebral trauma.&#xD;
&#xD;
          -  Myocardial infarction within 1 year prior to the screening visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Rucker, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James Rucker</last_name>
    <phone>+442032991851</phone>
    <email>kingscrf@kcl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Facility, King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Rucker, MD</last_name>
      <phone>+442032991851</phone>
      <email>kingscrf@kcl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psilocybin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

